Utility of 11C-Methionine PET in assessing malignancy of tumors

Utility of 11C-Methionine PET in assessing malignancy of tumors - Utility of 11C-Methionine PET in assessing malignancy of tumors

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000020581

Enrollment

150

Registered

2016-01-16

Start date

2016-01-20

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Brain tumor, Head and neck cancer, lung cancer, soft tissue tumor, pancreas cancer

Interventions

11C-Methionine

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who have malignant tumors or are suspected to have malignant tumors. Target disease: brain tumors, head and neck tumors, lung cancer, soft tissue tumor, pancreas cancer Patients who agree and write informed consent form Age >10 year-old If subjects are child, their parent or guardian write informed consent form

Exclusion criteria

Exclusion criteria: Pregnancy Claustrophobia Patient who can not keep still during the examination Performance Status >3 Patients who are not informed to have malignancy, if applicable MRI contradiction 1 Heart pacemaker 2 artificial ear 3 artificial hear valve 4 clip for cerebral aneurysm 5 artificial denture/implant 6 tattoo 7 other metals

Design outcomes

Primary

Measure	Time frame
Methionine uptake in tumors (visual assessment, SUV quantification, uptake count)	—

Secondary

Measure	Time frame
1) histological malignancy 2) FDG uptake in tumors 3) ADC measurements by diffusion-weighted MRI	—

Countries

Japan

Contacts

Public ContactOsamu Togao

Kyushu University Hospital Radiology

togao@radiol.med.kyushu-u.ac.jp092-642-5695

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026